1Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea
2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Internal Medicine, Hanmaeum Hospital, Jeju, Korea
Copyright © 2015 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variable | No. (%) |
---|---|
Multisegmental cholangitis | 21 (55.1) |
For drainage of contrast media | 4 (10.5) |
Hemobilia | 3 (7.9) |
Mirizzi’ s syndrome | 3 (7.9) |
Cholangiography | 4 (10.5) |
Uncontrolled jaundice | 3 (7.9) |
No. (%) | |
---|---|
Procedure related complications | 10 (26.3) |
Elevation of amylase/lipase (no symptom) | 7 (18.4) |
Overt pancreatitis | 1 (2.6) |
Bleeding | 0 |
Self removal of catheter | 2 (5.3) |
Significant change of electrolyte | 0 |
Post-ERCP cholangitisa) | 0/14 |
Characteristic | Value |
---|---|
No. of patients | 38 |
Age, yr | 58.29±11.0 |
Sex, male:female | 26:12 |
Underlying disease | |
Hilar cholangiocarcinoma | 20 (52.6) |
HCC with bile duct invasion | 12 (31.6) |
Stricture of anastomotic site following LT | 3 (7.9) |
Acute cholecystitis | 3 (7.9) |
Previous biliary stenting | 16 (42.1) |
White blood cell count, /mm3 | 7,662.7±3,497.0 |
Total bilirubin, mg/dL | 9.8±8.0 |
Aspartate transaminase, IU/L | 129.7±173.9 |
Alanine transaminase, IU/L | 112.5±137.5 |
Endoscopic sphincterotomy during procedure | 9 (23.7) |
Variable | No. (%) |
---|---|
Multisegmental cholangitis | 21 (55.1) |
For drainage of contrast media | 4 (10.5) |
Hemobilia | 3 (7.9) |
Mirizzi’ s syndrome | 3 (7.9) |
Cholangiography | 4 (10.5) |
Uncontrolled jaundice | 3 (7.9) |
Variable | Pre-double ENBD | Post-double ENBD | p-value | |
---|---|---|---|---|
WBC count, /mm3 | 8,622.22±3,805.34 | 7,675.00±3,882.88 | 0.247 | |
Total bilirubin, mg/dL | 10.86±9.89 | 8.72±11.61 | 0.208 | |
AST, IU/L | 123.03±175.23 | 328.03±1362.56 | 0.379 | |
ALT, IU/L | 107.64±142.16 | 172.00±631.79 | 0.557 | |
Duration | 14.92±15.24 | - |
Variable | HCC | p-value | CCA | p-value | Stricture of anastomosis | p-value | Mirizzi syndrome | p-value |
---|---|---|---|---|---|---|---|---|
Number | 12 | 20 | 3 | 3 | ||||
Duration | 15.2±13.2 | 10.5±10.8 | 46.3±18.8 | 12.3±13.6 | ||||
WBC count, /mm3 | ||||||||
Pre | 9,772.7±4,951.8 | 0.201 | 8,236.8±2,838.7 | 0.862 | 4,600.0±2,621.0 | 0.531 | 10,866.7±3,300.5 | 0.120 |
Post | 7,427.3±4,390.0 | 8,121.1±3,117.8 | 8,333.3±8,179.5 | 5,100.0±519.6 | ||||
Total bilirubin, mg/dL | ||||||||
Pre | 14.06±10.46 | 0.209 | 8.37±8.34 | 0.032 | 22.90±10.14 | 0.433 | 2.70±1.91 | 0.218 |
Post | 17.88±15.68 | 3.73±3.55 | 13.17±12.08 | 0.87±0.25 | ||||
AST, IU/L | ||||||||
Pre | 155.7±127.1 | 0.533 | 66.5±59.5 | 0.086 | 69.0±43.0 | 0.426 | 415.0±504.4 | 0.312 |
Post | 233.9±399.9 | 47.7±42.8 | 2,748.3±4,685.8 | 28.3±4.9 | ||||
ALT, IU/L | ||||||||
Pre | 106.0±119.4 | 0.762 | 68.7±61.7 | 0.027 | 85.0±74.6 | 0.443 | 382.7±337.6 | 0.199 |
Post | 93.0±101.9 | 53.4±55.7 | 1,303.0±2,191.1 | 81.7±75.5 |
Double ENBD | No. (%) |
---|---|
Indications of double ENBD | |
Multisegmental cholangitis | 12 (60) |
For drainage of contrast media | 4 (20) |
Cholangiography after PDT | 3 (15) |
Temporary drainage after PDT | 1 (5) |
Bismuth classification | |
II | 2 (10) |
IIIa | 9 (45) |
IIIb | 1 (5) |
IV | 8 (40) |
No. (%) | |
---|---|
Procedure related complications | 10 (26.3) |
Elevation of amylase/lipase (no symptom) | 7 (18.4) |
Overt pancreatitis | 1 (2.6) |
Bleeding | 0 |
Self removal of catheter | 2 (5.3) |
Significant change of electrolyte | 0 |
Post-ERCP cholangitis |
0/14 |
Values are presented as mean±SD or number (%). HCC, hepatocellular carcinoma; LT, liver transplantation.
Values are presented as mean±SD. ENBD, endoscopic nasobiliary drainage; WBC, white blood cell; AST, aspartate transaminase; ALT, alanine transaminase.
Values are presented as mean±SD. HCC, hepatocellular carcinoma; CCA, cholangiocarcinoma; WBC, white blood cell; AST, aspartate transaminase; ALT, alanine transaminase.
ENBD, endoscopic nasobiliary drainage; PDT, photodynamic therapy.
ERCP, endoscopic retrograde cholangiopancreatography. Excluding 24 patients who presented with cholangitis initially.